Novartis interacts with many patient groups. These groups play a crucial role by informing and supporting patients, as well as safeguarding the rights of patients and caregivers. Further, patient groups provide pharmaceutical companies with important advice from their own perspective.

Interacting with patient organizations enables Novartis to learn about unmet patient needs, and this information can guide us in the development of new medicines.

In all our interactions with patient groups, we are committed to working ethically and transparently while respecting their integrity. With regards to the disclosure of patient group support, Novartis is fully compliant with all legal and statutory requirements as a minimum standard in a given country. We commit to disclose the names of patient groups that have received funding or non-monetary support from Novartis as well as the purpose of this support in Europe, the US and for international groups. This list is updated annually.

Read our position on Patient group interaction and support
(62 KB)